
    
      Open, randomized, multicentric, controlled trial. Infants will be randomly allocated in one
      of the two study groups as follows:

      Group A: 212 subjects will receive the PENTAXIM™ vaccine at 6, 10 and 14 weeks of age, and
      the recombinant 10 µg hepatitis B vaccine at 0, 6 and 14 weeks of age.

      Group B: 212 subjects will receive the PENTAXIM™ and the recombinant 10 µg hepatitis B
      vaccines at 6, 10 and 14 weeks of age.

      All infants included in the study will receive a booster dose of PENTAXIM™ vaccine at 18-19
      months of age.
    
  